Register For Our Mailing List

Register to receive our free weekly newsletter including editorials.

Home / 678

Why investors are looking beyond traditional property sectors

What is life sciences real estate?

Life sciences real estate is characterised by facilities largely used for scientific research, diagnostics, healthcare, and innovation — most commonly in biotechnology, pharmaceuticals, medical technology and pathology. These assets are classified within the ‘alternative’ real estate sector, sitting between Office, Retail and Industrial & Logistics sectors, and are distinct from traditional healthcare real estate (e.g. hospitals and aged care).

Life sciences assets are comparatively more complex and sophisticated, with higher upfront capital requirements from the tenant. They can accommodate laboratories (wet and dry), Research and Development (R&D) facilities, biomanufacturing plants, clean rooms, testing facilities, and specialised office-lab hybrid buildings. These uses often require advanced heating, ventilation, and air conditioning (HVAC) control systems, high power capacity with backup infrastructure, and specialised safety features. Assets may also require reinforced floors and be subject to strict regulatory compliance. Typically, they are located within established clusters in close proximity to research institutions, universities, hospitals and skilled labour forces.

While life sciences property encompasses biotechnology and pharmaceutical research, this article focuses primarily on pathology and diagnostic testing facilities, which represent one of Australia’s most established forms of life science infrastructure.


Sullivan Nicolaides Pathology, 24 Markwell Street, Bowen Hills Qld

Structural demand drivers

The sector benefits from several long-term structural trends that may support demand growth. Ageing populations and rising healthcare demand have driven significant increases in healthcare expenditure. In the wake of the pandemic, there has also been an increased focus on longevity trends and a marked expansion in the scale and complexity of medical testing.

Long-term trends supporting demand

  • Ageing population: Australia’s population aged 65+ will increase from 1 in 6 today to 1 in 4 Australians by the 2060s, with 85+ the fastest growing cohort.1 This rise in the elderly population is expected to drive structurally higher and recurring demand for pathology and diagnostic testing.
  • Leading government healthcare spending and performance: Australia has recorded the highest growth in healthcare spending per capita across the advanced economies, increasing 5.7% compound average growth rate (CAGR) since 2000, above the G12 average of 5%.2 Australia also has an outperforming and productive health system, ranked highly for health outcomes, equity and efficiency.3
  • Variety and complexity of testing: Growth in diagnostic testing reflects increasing variety and complexity (e.g. genomic monitoring and biomarkers, multi-panel testing), as well as the expansion of screening programs and early detection initiatives. Preventative healthcare is shifting upstream with an increasing focus on early intervention, which is expected to support testing volumes.

Life sciences real estate as an investment sector

Life sciences real estate is a diverse property sector, and the method of participation for an investor is a key determinant of outcomes. The sector’s specialisation and higher upfront capital requirements create distinct investment implications. Tenant lease terms are generally longer, increasing the importance of tenant financial stability, asset specialisation and location.

  • Tenant quality: High-quality tenants reinvest in mission-critical assets, underpinning sustainable rents and long-term cash flow growth. Key indicators of tenant strength include rent-to-EBITDA (earnings before interest, taxes, depreciation and amortisation) and net debt-to-EBITDA ratios. Over time, high-quality tenants with resilient business models tend to deliver EBITDA growth, which may strengthen income security and support rental growth.
  • Asset specialisation: The specification, regulation and capital requirements create barriers to entry across the asset class. As a result, well-located, high-quality facilities may be better positioned to command rental premiums and support occupancy over the long term.
  • Location: Over time, tenant network effects may strengthen as connections with customers and surrounding business clusters deepen, reinforcing locational dependence and supply chain networks. Immediate proximity to key hospitals, medical research institutions and tertiary health services strengthens operational linkages and increases the strategic importance of the location to tenants.

Conversely, underperforming tenants can materially impair outcomes. In the event of lease expiry, high fit-out costs and asset-specific requirements can result in elevated re-leasing costs. Where assets are in inferior locations or poor condition, these challenges can compound. Tenant concentration and dependence on government reimbursement settings may also represent risks.

Successful investment criteria

Successful investments are typically anchored by tenants with strong and diversified revenue sources. Their cash flows tend to be supported by both public and private funding sources.

Investment risk can be mitigated through careful asset and tenant selection. Greater conviction can be achieved by targeting essential business models with established track records, and by prioritising modern, stabilised assets that reduce development-related risks.

Why pathology facilities may benefit from structural demand

Demand for essential pathology services

  • Critical life sciences infrastructure: Australia’s private pathology sector provides essential healthcare infrastructure for illness detection and treatment.
  • Non-discretionary demand: Consumption of these services has been resilient through economic cycles, with a strong link to population growth, ageing population, rising life expectancy, and ongoing technological advancements.
  • High barriers to entry and limited supply: Significant capital requirements, stringent regulation, specialised facility requirements and scarce suitable real estate constrain new supply, contributing to a highly concentrated market in which the three largest operators account for more than three-quarters of industry revenue.

Healthcare expenditure and service usage

  • Ongoing government fiscal commitments: The FY27 Federal Government budget for healthcare increased commitments, with an approximate 17% increase in health expenditure forecast between FY26 and FY30.1
  • Rise in service usage: Pathology services provided under Medicare have trended upwards over the past decade. Over the 20 years to FY25, the average annual number of Medicare pathology items claimed per person increased 75%, from 2.6 items to 4.6 items per person.3 In FY25 alone, 175 million services were provided under Medicare.4
  • Medicare expenditure: Approximately $3-4 billion per year is spent on Medicare-funded pathology in Australia. This equates to roughly 10-12% of total Medicare expenditure, the joint highest service volumes per capita with GP visits.5
  • Growth of market: Australia’s pathology market is worth ~US$11.8 billion in 2025 and is forecast to grow to US$26.2 billion by 2034 (~9% CAGR).6

Public and private funding sources

  • Public support: Given the focus on maintaining sustainable healthcare expenditure, governments may increasingly rely on efficient, private providers to deliver healthcare services.
  • Medicare support: Pathology has resilient support from government funding through Medicare (~70-90% of volume), with pathology traditionally recording one of the highest bulk-billing rates of any medical service (~91% in FY24, compared with an average of ~76% across other services).1
  • Resilient government funding: The government continues to commit to expanding test coverage, adding new reimbursable tests, and supporting access and volumes. Examples include Medicare-funded reproductive carrier screening tests and higher demand for genetic testing. However, reimbursement levels are subject to policy decisions and periodic review.
  • Private sector filling the gaps: The private sector is also contributing to service funding, with a growing contribution from private insurance (via hospital diagnostics) and advanced diagnostics.

Together, these factors suggest that pathology facilities may benefit from supportive, long-term demand trends. However, as with any specialised sector, investment outcomes will depend on asset quality, tenant strength, valuation discipline and future supply conditions.

 

1. Australian Government – Australian Institute of Health & Welfare FY27 Government Budget.
2. Global Health Expenditure WHO, via World Bank 2026.
3. Commonwealth Fund – Healthcare system performance rankings.
4. IbisWorld.
5. Services Australia.
6. Imarc Group.

Steven Bennett is Chief Executive of Direct Property and Sasanka Liyanage is Head of Research at Charter Hall Group, a sponsor of Firstlinks. This article is for general information purposes only and does not consider the circumstances of any person, and investors should take professional investment advice before acting.

For more articles and papers from Charter Hall, please click here.

 

  •   2 September 2026
  • 1
  •      
  •   

RELATED ARTICLES

The first impact of negative gearing reform is not the tax bill

Origins of the mislabeled capital gains tax ‘discount’

Australian house price speculators: What were you thinking?

banner

Most viewed in recent weeks

Division 296: the initial moves to make before the windows close

What if the best superannuation strategy isn't about earning more, but acting before your options disappear? Several overlooked planning windows are narrowing, with consequences that can last for decades.

The retirement scorecard: how many of these questions can you answer?

From the maths of retirement, estimating spending and picking the right asset allocation to survive a poor decade, here are the questions every retiree – current or future – should be able to answer for themselves.

Testamentary trusts: Treasury has picked the wrong reading

A decades-old estate planning tool has survived one tax crackdown only to be caught by another. The surprise isn't who the reform is targeting, but who could end up paying the price for drafting choices made years ago.

Superannuation’s structural failings

Politicians are fighting over access to super, but they may be arguing about the wrong thing. The system’s three fundamental flaws have been hiding in plain sight for decades, costing Australians far more than they realise.

Avoid unnecessary CGT with this estate planning clause

A simple estate plan can create a ticking time bomb. One overlooked clause can pit spouses against children, delay inheritances, and potentially leave a family facing an unexpected tax bill worth hundreds of thousands of dollars.

Does an American retirement rule work for Australians?

The 4% rule has survived decades of scrutiny, but Australia's retirement system changes the equation in ways most overlook. Before accepting or rejecting this rule of thumb, it pays to understand what really drives retirement outcomes.

Latest Updates

Superannuation

Bill Kelty: Super can't solve everyone's problems

One of the key figures behind Australia’s superannuation system reflects on how it began, what has changed, and why some of today’s biggest debates may be asking too much of a retirement savings system.

Investment strategies

Rising yields have put bonds back in business

For the past decade, investors were forced to chase income wherever they could find it. With yields now offering competition to dividends, the new challenge is deciding whether they're still being adequately rewarded for risk.

Strategy

Do you want a bucket with that?

Retirees, advisers and super funds all talk about the bucket strategy as if it's one thing. It's not. The differences can be significant, and some may matter far more than investors realise when markets become volatile.

Investment strategies

What The Odyssey can teach us about valuation discipline

Investment temptations are hard to resist in the moment, but successful investing is not about ignoring compelling opportunities or ideas. For value investors, the smart move is to prepare before momentum clouds judgement.

Shares

Does market concentration really mean more risk for investors?

One of the most closely watched trends in global markets has become a growing source of investor concern in recent years. Whether that concern is justified, however, turns out to be a far more complicated question.

Retirement

Retirement in reality - 8 months in

Health goals, new friendships and lingering questions about identity have dominated this month. The experience has challenged widely held beliefs about purpose, belonging and what it really means to leave work behind.

Shares

Stagnation might be OK at this point

Australia's economic problems are hardly a secret. The more interesting question for investors is whether the stock market is as exposed to those problems as commonly assumed, or whether the picture is more nuanced.

Sponsors

Alliances

  • ASA-Logo-RGB-ActiveGreen-web.png

© 2026 Morningstar, Inc. All rights reserved.

Disclaimer
The data, research and opinions provided here are for information purposes; are not an offer to buy or sell a security; and are not warranted to be correct, complete or accurate. Morningstar, its affiliates, and third-party content providers are not responsible for any investment decisions, damages or losses resulting from, or related to, the data and analyses or their use. To the extent any content is general advice, it has been prepared for clients of Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892), without reference to your financial objectives, situation or needs. For more information refer to our Financial Services Guide. You should consider the advice in light of these matters and if applicable, the relevant Product Disclosure Statement before making any decision to invest. Past performance does not necessarily indicate a financial product’s future performance. To obtain advice tailored to your situation, contact a professional financial adviser. Articles are current as at date of publication.
This website contains information and opinions provided by third parties. Inclusion of this information does not necessarily represent Morningstar’s positions, strategies or opinions and should not be considered an endorsement by Morningstar.